This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A seismic shift has occurred in the healthcare landscape. Delivering on these heightened expectations has fueled the urgency to invest in patient engagement and support.
Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patienthealthcare solution - sat down with Fierce at Digital Phar | Matthew Walsh, General Manager of Biopharma at Ixlayer – a cloud-based platform specialist empowering operational efficiency, patient access, and improved outcomes (..)
Artificial intelligence (AI) has enormous potential in healthcare, but all too often, it gets misunderstood. With the right infrastructure, intelligent tools stand to not only process data but also improve clinical decision-making—helping find more patients for biopharma companies, and faster, too.
Wearable patient devices can provide healthcare organizations with more varied data, expand options for clinical trials, and make patients more active participants in their own care.
Science has taken a vertical growth trajectory, yet such innovations are, at best, slow to reach the patients in need. We believe that innovation in patient access models is the necessary catalyst to aid patients in starting on and staying on the therapies they need to improve their lives.
The problem with the US healthcare system is one of misaligned incentives. Prescribers are paid to evaluate patients and to administer care. All prescribers want the best outcomes for their patients, but the system does not incentivize choosing the best medications to promote those outcomes.
With promises of more efficient and reliable diagnoses, future breakthroughs in personalized medicine and targeted therapeutics, and an expedited R&D lifecycle, industry leaders must be prepared to invest in quantum technologies to deliver better outcomes for their organizations and patients.
By fostering collaboration and seamless data integration into healthcare systems, the industry is laying the groundwork for a future in which “personalized medicine” is so commonplace within clinical practice that we will just start calling it “medicine.”
The term “patient centricity” has been around for over a decade, and since its first utterance the buzzword has been praised, dissected, criticized, and everything in between. The concept has always been worthwhile, but people within and outside of the industry have wondered whether the industry was truly becoming more patient centric?
OpenAI’s launch of ChatGPT on March 14 heralds a new era of artificial intelligence that will have profound implications for society, including the life science and healthcare industries. Our customers entrust our products and services to help them improve patient health, and we will not jeopardize that mission.
Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. Innovation Is Expanding, But Healthcare Systems Are Slow to Adapt. Driving scale in a slow-moving healthcare ecosystem is not just a challenge for cell and gene therapies.
Embarking on the journey from product development to market success in the biopharma industry is no small feat. According to a McKinsey report , a startling 40% of biopharma products fail to meet their sales forecasts within the initial two years, prompting a critical reassessment of strategies for product launches.
When diversity is well-implemented in healthcare materials, trust is built and patient-provider relationships improve. It also enhances the medical accuracy of the information presented.
They are going to allow Biogen NINE years for follow-up clinical trials in which time our healthcare system is going to pay a TON of money for hope. There are no efficacy data to clearly demonstrate this drug helps patients. Over that 9 years, Biogen can squeeze patients and payers for their $56,000 price. Nowhere to be seen.
invoX Pharma has signed a definitive agreement for the acquisition of all issued and outstanding shares of clinical-stage biopharma firm F-star Therapeutics, in a deal valued at nearly $161m or $7.12 The post invoX Pharma agrees to acquire biopharma firm F-star Therapeutics for $161m appeared first on Pharmaceutical Technology.
In recent years, there has been an increased focus on real world evidence to advance medical science and improve patient quality of life. Biopharma companies are investing in the use of real world data (RWD) to accelerate innovation. The treatment of patients experiencing acute disease is quite dynamic.
We can apply this approach in pharma by enhancing our patient journey maps and go beyond focusing on the key clinical engagement touch points (e.g., doctor visits, prescription pickups) and enriching our insights with the micro-moments surrounding these obvious events.
This is especially relevant in biopharmaceutical patient engagement, where regulatory infractions can have existential consequences. The Unique Challenges of Patient/Pharma Interaction Patient engagement has become a critical component of medical marketing.
The product, produced by biopharma company PTC Therapeutics, is approved for patients 18 months and over. It has been granted marketing authorisation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Upstaza clinical trials.
healthcare payers and providers are consolidating at a dizzying clip as they seek to gain market share, increase access to care and secure clinical control to improve health outcomes. billion deal to acquire Oak Street Health, a value-based primary-care company focused on treating Medicare patients.
In our latest podcast, Ideas to Innovation, we speak with Dr. Grace Lomax, the clinical director at Patient Connect, part of Clarivate. Grace tells us about her experience as a physician and discusses healthcare literacy and education at the point of care. Supporting patients at the point of care. Dr. Grace Lomax.
But the role of AI in healthcare will go beyond this. healthcare, with its 17% share of GDP, is “the most disruptable industry in the world,” and “the first big carcass that AI is going to start to feed on.” Patients can look forward to electronic assistance that can return their voice or other lost abilities.
To realize true, sustainable savings in total cost of care, the healthcare system needs to reconsider the support — or lack of support — it provides throughout patients’ medication experiences and the snowball effect that creates on a lifetime of healthcare costs.
From connecting with patients by interactive ads to dabbling into cross-platform integration, here is what our specialists had to say. What are new and effective ways of engaging patients who are now using streaming services? Biopharma marketers are following their audiences and investment in this channel continues to increase.
CBC CEO Fu Wei stated: “Hasten is a well-established Chinese biopharma company with tremendous growth potential. Hasten will also use the proceeds from the round to fund future acquisitions. The firm reported 47% growth in sales from Q2 to Q4 in 2022, which is testament to CBC’s unique and effective investor-operator strategy.
For patients who may be unable to afford the high cost of GLP-1 obesity drugs or are worried about the side effects, it’s important for healthcare providers to offer education on herbal alternatives and consider these as part of the broader treatment conversation. appeared first on MedCity News.
The adoption of eCOA technology in mental healthcare research can make pivotal advancements in mental health patient care. Electronic Clinical Outcomes Assessment and digital health tools were well-suited to accommodate the rapid rise of virtual and telehealth shifts during the Covid-19 pandemic and there is no going back.
The Hippocratic oath can’t stop with direct patient care; the healthcare industry and its key stakeholders must address persistent public health problems systematically. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority.
The European Commission (EC) has now granted a marketing authorisation for biopharma company UCB’s treatment, as an add-on to standard therapy in patients who have this rare autoimmune condition. It is indicated as a subcutaneous, add-on to standard therapy in these patients.
There is a huge opportunity for PBMs and health systems to use AI to help address the challenges surrounding the affordability and accessibility of medicines, from navigating formularies to resolving prior authorization. More automation in pharmacies and with ordering workflows is one piece of that puzzle.
The pandemic showed that the healthcare system can respond and evolve when confronted by an existential threat. It’s time to fundamentally improve the cancer journey, while ensuring that resources are used more wisely.
We cannot change the fact that some patients must take multiple drugs, but we can certainly change how we manage it with careful coordination and communication among healthcare providers, and personalized medicine practices such as pharmacogenomics.
Now, the two companies will unite their full suite of advisory, medical, marketing, communications, and patient and stakeholder engagement services to create a new organization called Inizio. It includes companies Vynamic, Research Partnership, Putnam Associates, and STEM Healthcare.
Ittai Dayan , Co-founder & CEO of Rhino Health , shared how his company is transforming the way healthcare AI solutions are created, adopted and measured. For example, taking a patient registry, you work on re-structured data and then add to that, imaging data. If you enjoyed this episode, kindly leave a review on iTunes.
The Healthcare Businesswomen’s Association (HBA) has appointed Mary Stutts as Chief Executive Officer where she will lead the global association’s mission to accelerate the advancement and impact of women in the business of healthcare. Morgan Healthcare Conference.
In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance.
The pandemic has worsened the healthcare inequities facing many marginalized communities, including Black Americans. Telehealth offers one means of addressing disparities – but healthcare stakeholders must step up to make it sustainable and effective in closing the gaps. In a recent Clarivate survey, U.S.
This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. Marketing to rare disease patient populations is equal parts opportunity and responsibility. audiences (direct-to-patient advertising rules are fundamentally different overseas).
Many of biopharma’s most exciting innovations come from the field of rare and ultra-rare diseases like Marc’s. With the development of new technology platforms at breakneck speed, companies are positioning themselves to one day deliver game-changing solutions to patients in their niche—solutions they may have been waiting for all their life.
Dr Prasanth Reddy, head of oncology at LabCorp, tells us how the company works with cancer care teams, biopharma partners, and patients as an integral part of the patient journey from testing to treatment. The test is conducted in a care provider’s office or our patient service centres (PSC). Tailored oncology.
This article explores the benefits of implementing RFID in healthcare settings and how hospitals can gradually transition from barcode to RFID-enabled medication systems, leading to substantial cost savings and improved patient care.
From enabling patient choice during clinical trials to strengthening vital partnerships across the quality ecosystem, connected data will become the lifeblood that enables life sciences teams to collaborate efficiently and effectively in 2023. Patient choice will push sponsors toward operational excellence.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content